Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baxdrostat - CinCor Pharma

Next Previous
X
Search
Drug Profile

Baxdrostat - CinCor Pharma

Alternative Names: CIN-107

Latest Information Update: 26 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer AstraZeneca; CinCor Pharma; CinRx Pharma
  • Class Amides; Antihypertensives; Antisecretories; Isoquinolines; Small molecules
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension; Renal failure
  • Phase II Hyperaldosteronism
  • No development reported Spinal cord disorders

Most Recent Events

  • 19 Dec 2024 AstraZeneca plans a phase III trial in Hypertension and Kidney disorders (Combination therapy) in USA (PO, Tablets) in March 2025(NCT06742723)
  • 06 Nov 2024 AstraZeneca plans the phase III Prevent-HF trial in Heart failure (Combination-therapy, Prevention) in Argentina, Australia, Bulgaria, Canada, Germany, Greece, Italy, Malaysia, Netherlands, Philippines, South Africa, Thailand (PO, Tablet), in March 2025 (NCT06677060)
  • 01 Nov 2024 AstraZeneca initiates a phase I pharmacokinetic trial (In volunteers) in USA (PO) (NCT06657105)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top